彩神lll正规的

彩神8app官网下岳阳

Home/Investors/ Press Releases

彩神8app官网下岳阳

  • Company Information
  • Financial Information
  • Stock Data
  • Analyst Coverage
  • SEC Filings
  • Corporate Governance
    • 4Dec

    CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel彩神8app官网下岳阳

    13Nov

    CymaBay Therapeutics to Present at Three Investor Conferences彩神8app官网下岳阳

    8Nov

    CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates彩神8app官网下岳阳

    1Nov

    CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8彩神8app官网下岳阳

    31Oct

    CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer彩神8app官网下岳阳

    23Oct

    CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis彩神8app官网下岳阳

    9Oct

    CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting彩神8app官网下岳阳

    18Sep

    CymaBay Therapeutics to Present at Two Investor Conferences彩神8app官网下岳阳

    11Sep

    CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis彩神8app官网下岳阳

    15Aug

    CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology彩神8app官网下岳阳

    RSS
    Show All

    彩神8app官网下岳阳

    • 7575 Gateway Blvd., Suite 110
      Newark, CA 94560
    • +1 (510) 293-8800
    • +1 (510) 293-9090

    彩神8app官网下岳阳

    彩神8app官网下岳阳

    彩神8ll下载安卓彩神1怎么玩彩神2彩票邀请码彩神8官网版彩神88app下载彩神8顶尖团队计划